Real-world Evidence of Inebilizumab in IgG4-RD (REDUCE)
Real-world Evidence of Inebilizumab in Decreasing Corticosteroid Use and Improving Clinical Efficacy in IgG4-RD
The goal of this observational study is to observe the efficacy and safety of inebilizumab in the treatment of IgG4-related disease. The main question it aims to answer the optimal steroid-sparing regimen for patients with IgG4-RD in clinical practice.
This study will enroll all patients with IgG4-RD treated with inebilizumab. Enrolled patients will receive different treatment regimens according to disease severity and whether they are taking other immunosuppressive agents.
研究概览
地位
条件
详细说明
All enrolled patients will be categorized into four subtypes based on disease severity and concomitant use of other immunosuppressive agents:
Group1 Treatment-naive active disease treated with inebilizumab monotherapy group: treatment-naive patients or patients with post-discontinuation relapse, in whom the investigator assesses that the disease is suitable for inebilizumab monotherapy; Group2 Treatment-naive active disease treated with short-course corticosteroids plus inebilizumab group: treatment-naive patients or patients with post-discontinuation relapse, in whom the investigator assesses that short-course corticosteroids are required in combination; Group3 Stable disease continued-treatment group: patients with stable disease control on long-term corticosteroids or corticosteroids plus conventional immunosuppressants, who are at high risk of relapse after discontinuation and are willing to switch to a steroid-free inebilizumab treatment regimen; Group4 Relapsed/refractory patient group: patients who experience relapse while receiving corticosteroids or corticosteroids combined with immunosuppressants.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Linyi Peng
- 电话号码:+86-10-69155004
- 邮箱:drpenglinyi@163.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
All IgG4-related disease patients treated with inebilizumab.
描述
Inclusion Criteria:
- Aged ≥18 years old;
- Meet the 2019 ACR/EULAR classification criteria or the 2020 Japanese diagnostic criteria for IgG4-RD;
- Plan to receive treatment with inebilizumab;
- Signed informed consent form.
Exclusion Criteria:
- Pregnant or lactating female patients;
- Participation in other interventional studies within 30 days prior to screening, or exposure to investigational products within 5 half-lives before enrollment, or planned participation in other interventional studies during the trial period;
- Patients with contraindications to inebilizumab treatment;
- Any other conditions deemed inappropriate for enrollment by the investigator.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:CROSS_SECTIONAL
队列和干预
团体/队列 |
|---|
|
Patients with IgG4-RD treated with inebilizumab
Patients with IgG4-RD receiving inebilizumab in the real-world setting |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Relapse rate
大体时间:One year after inebilizumab treatment
|
Flare of IgG4-RD is defined as the reappearance of previous symptoms or signs of IgG4-RD or the appearance of new symptoms or signs attributed to IgG4-RD, based on clinical assessment, laboratory tests, and/or imaging, and reflected by an increase in the IgG4-RD Responder Index |
One year after inebilizumab treatment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of subjects achieving flare-free and treatment-free complete remission
大体时间:Three Months, six months and twelve months after inebilizumab treatment
|
Flare-free and treatment-free complete remission was defined as the absence of any disease flare, no glucocorticoid for flare, and the absence of disease activity |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Proportion of subjects achieving flare-free and glucocorticoid-free complete remission
大体时间:Three Months, six months and twelve months after inebilizumab treatment
|
Flare-free and glucocorticoid-free complete remission was defined as the absence of any disease flare, no glucocorticoid for flare, and the absence of disease activity |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Remission rate after inebilizumab treatment
大体时间:Six months and twelve months after inebilizumab treatment
|
The investigator determined that there was no evidence of disease activity at the visit |
Six months and twelve months after inebilizumab treatment
|
|
IgG4-RD Responder Index (IgG4-RD RI) after inebilizumab treatment
大体时间:Three Months, six months and twelve months after inebilizumab treatment
|
Measured by IgG4-RD Responder Index |
Three Months, six months and twelve months after inebilizumab treatment
|
|
IgG4-RD Damage Index (IgG4-RD DI) after inebilizumab treatment
大体时间:Three Months, six months and twelve months after inebilizumab treatment
|
Measured by IgG4-RD Damage Index |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Changes in serum IgG4 levels from baseline after inebilizumab treatment
大体时间:Three Months, six months and twelve months after inebilizumab treatment
|
Laboratory markers |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Changes in serum B-cell levels from baseline after inebilizumab treatment
大体时间:Three Months, six months and twelve months after inebilizumab treatment
|
Laboratory markers |
Three Months, six months and twelve months after inebilizumab treatment
|
|
Total amount of glucocorticoids during inebilizumab administration
大体时间:One year after inebilizumab treatment
|
Total amount of glucocorticoids calculated as the cumulative glucocorticoid dose (in milligrams) taken for the purpose of IgG4-RD disease control. This measure accounted for all glucocorticoids treatments administered to participants to manage disease activity throughout the study period. |
One year after inebilizumab treatment
|
|
Improvement in patients' quality of life during inebilizumab administration
大体时间:One year after inebilizumab treatment
|
Quality of life measured by the EQ-5D-5L questionnaire |
One year after inebilizumab treatment
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- I-26PJ0909
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD will not be shared with other researchers. Data may be made available to regulatory authorities, trial monitors, auditors, and ethics committees as required for trial oversight, monitoring, audit, and verification.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.